Analysis suggests high efficacy for single dose of Pfizer-BioNTech vaccine
An analysis by Canadian researchers suggests that a single dose of the Pfizer-BioNTech COVID-19 vaccine is highly efficacious, according to a letter published yesterday in the
New England Journal of Medicine (
NEJM).
Results from the phase 3 trial of the Pfizer-BioNTech vaccine, published in NEJM on Dec 31, 2020, suggested the efficacy after the first dose of the two-dose vaccine was 52.4%, based on data collected during the first 2 weeks after the first shot to before the second shot. The overall efficacy after two doses was 94.8%.
But in their analysis of trial data submitted to the US Food and Drug Administration by Pfizer and BioNTech, researchers with the British Columbia Centre for Disease Control and the Institut National de Santé Publique du Québec found that data collected starting 2 weeks after the first shot to before the second shot indicate the efficacy of the first dose was 92.6%. The res
TORONTO - A single jab of COVID-19 vaccine appears to be highly effective, which could allow better use of scarce supplies and see more people immunized,
Feds study data suggesting Pfizer vaccine may be almost as good after one dose as two humboldtjournal.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from humboldtjournal.ca Daily Mail and Mail on Sunday newspapers.
Feds study data suggesting Pfizer vaccine may be almost as good after one dose as two toronto.citynews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from toronto.citynews.ca Daily Mail and Mail on Sunday newspapers.